Oct 20, 2025

Cordis Unveils Positive Results for Two SELUTON SLR DEB Trials

Cordis Unveiled Breakthrough Results from SELUTION DENOVO and SELUTION4ISR Trials at TCT 2025.

Read more

Oct 20, 2025

Cordis to Unveil 12-Month SELUTION SLR DEB Trial Results

Cordis to unveil 12-month results from two SELUTION SLR^™ DEB randomized clinical trials at TCT 2025 Late-Breaking Clinical Trials Session

Read more

May 19, 2025

Cordis Launches Global Coronary Registry for SELUTION SLR™ Drug-Eluting Balloon

This Global Coronary Registry will enroll up to 10,000 patients worldwide and will be one of the largest coronary drug-eluting balloon registries to date.

Read more

Apr 24, 2025

Cordis Announces Positive Results from Two Major Clinical Studies.

Cordis Announces Positive Results from Two Major Studies Demonstrating Durable Efficacy of SELUTION SLR Drug-Eluting Balloon in Complex Peripheral Artery Disease Patients.

Read more

Jul 16, 2024

Cordis Awarded Vascular Closure Devices Agreement with Premier, Inc. for MYNX CONTROL™ VENOUS Vascular Closure Device

Read more

Jun 18, 2024

Cordis Announces Positive 24-Month Results from the SELUTION Superficial Femoral Artery (SFA) Japan Study

Read more

Nov 16, 2023

Cordis Announces Enrollment Completion of the RADIANCY Clinical Study in Europe

Read more

Nov 6, 2023

Cordis Announces Scott Drake as Chief Executive Officer

Cordis Announces Scott Drake as Chief Executive Officer

Read more

Oct 31, 2023

World's First Patient Enrolled in SELUTION4DeNovo DEB IDE Trial

Read more